RT Journal Article
SR Electronic
T1 Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.02.20166819
DO 10.1101/2020.08.02.20166819
A1 Zeng, Cong
A1 Evans, John P.
A1 Pearson, Rebecca
A1 Qu, Panke
A1 Zheng, Yi-Min
A1 Robinson, Richard T.
A1 Hall-Stoodley, Luanne
A1 Yount, Jacob
A1 Pannu, Sonal
A1 Mallampalli, Rama K.
A1 Saif, Linda
A1 Oltz, Eugene
A1 Lozanski, Gerard
A1 Liu, Shan-Lu
YR 2020
UL http://medrxiv.org/content/early/2020/08/04/2020.08.02.20166819.abstract
AB Rapid and specific antibody testing is crucial for improved understanding, control, and treatment of COVID-19 pathogenesis. Herein, we describe and apply a rapid, sensitive, and accurate virus neutralization assay for SARS-CoV-2 antibodies. The new assay is based on an HIV-1 lentiviral vector that contains a secreted intron Gaussia luciferase or secreted Nano-luciferase reporter cassette, pseudotyped with the SARS-CoV-2 spike (S) glycoprotein, and is validated with a plaque reduction assay using an authentic, infectious SARS-CoV-2 strain. The new assay was used to evaluate SARS-CoV-2 antibodies in serum from individuals with a broad range of COVID-19 symptoms, including intensive care unit (ICU) patients, health care workers (HCWs), and convalescent plasma donors. The highest neutralizing antibody titers were observed among ICU patients, followed by general hospitalized patients, HCWs and convalescent plasma donors. Our study highlights a wide phenotypic variation in human antibody responses against SARS-CoV-2, and demonstrates the efficacy of a novel lentivirus pseudotype assay for high-throughput serological surveys of neutralizing antibody titers in large cohorts.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted under The Ohio State University IRB #2020H228.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe agree that all data will be made available upon request.